[{"id":"691969a6-dc3e-4580-99bb-0a9ff4f0cef1","acronym":"NIRADO","url":"https://clinicaltrials.gov/study/NCT04779151","created_at":"2021-03-03T13:57:08.218Z","updated_at":"2024-07-02T16:35:12.913Z","phase":"Phase 2","brief_title":"Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab","source_id_and_acronym":"NCT04779151 - NIRADO","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Suspended","enrollment":" Enrollment 51","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-03-26"},{"id":"12441980-737d-4616-9bf1-f93f67db0099","acronym":"","url":"https://clinicaltrials.gov/study/NCT01665703","created_at":"2021-01-18T07:12:01.461Z","updated_at":"2024-07-02T16:36:36.476Z","phase":"","brief_title":"Imaging Correlates of Renal Cell Carcinoma Biological Features","source_id_and_acronym":"NCT01665703","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PBRM1 • KMT2D • HIF1A • SETD2 • MLL2","pipe":" | ","alterations":" KMT2D mutation • PBRM1 mutation • VHL mutation • HIF1A expression","tags":["PBRM1 • KMT2D • HIF1A • SETD2 • MLL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2D mutation • PBRM1 mutation • VHL mutation • HIF1A expression"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2021-01-07"}]